keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma Outcomes

keyword
https://read.qxmd.com/read/30785830/radiotherapy-or-autologous-stem-cell-transplantation-for-primary-cns-lymphoma-in-patients-60-years-of-age-and-younger-results-of-the-intergroup-anocef-goelams-randomized-phase-ii-precis-study
#1
Caroline Houillier, Luc Taillandier, Sylvain Dureau, Thierry Lamy, Mouna Laadhari, Olivier Chinot, Cecile Moluçon-Chabrot, Pierre Soubeyran, Remy Gressin, Sylvain Choquet, Gandhi Damaj, Antoine Thyss, Julie Abraham, Vincent Delwail, Emmanuel Gyan, Laurence Sanhes, Jérôme Cornillon, Reda Garidi, Alain Delmer, Marie-Laure Tanguy, Ahmad Al Jijakli, Pierre Morel, Pascal Bourquard, Marie-Pierre Moles, Adrien Chauchet, Thomas Gastinne, Jean-Marc Constans, Adriana Langer, Antoine Martin, Patricia Moisson, Lucette Lacomblez, Nadine Martin-Duverneuil, Daniel Delgadillo, Isabelle Turbiez, Loïc Feuvret, Nathalie Cassoux, Valérie Touitou, Damien Ricard, Khê Hoang-Xuan, Carole Soussain
PURPOSE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 mg/m2 D2, BCNU 100 mg/m2 D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m2 D1, cytarabine 3 g/m2 D1 to D2)...
February 20, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30784598/mass-cytometry-analysis-reveals-that-specific-intratumoral-cd4-t-cell-subsets-correlate-with-patient-survival-in-follicular-lymphoma
#2
Zhi-Zhang Yang, Hyo Jin Kim, Jose C Villasboas, Tammy Price-Troska, Shahrzad Jalali, Hongyan Wu, Rebecca A Luchtel, Mei-Yin C Polley, Anne J Novak, Stephen M Ansell
Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4+ T cells, 3 of which were unique to FL biopsies versus control tissues. Of these subsets, the frequency of naive T cells correlated with improved patient survival. Although total PD-1+ T cell numbers were not associated with patient outcome, specific PD-1+ T cell subpopulations were associated with poor survival...
February 19, 2019: Cell Reports
https://read.qxmd.com/read/30783026/primary-cns-lymphoma-in-the-elderly-the-challenge
#3
REVIEW
Tali Siegal, Osnat Bairey
Primary central nervous system (CNS) lymphoma is an aggressive brain tumor sensitive to chemotherapy and radiotherapy. Its incidence has increased in the elderly, and they account for the majority of patients. The median survival of patients older than 70 years did not change over the last 40 years and remained in the range of 6-7 months. The definition of elderly is nonuniform, and chronological age is not the best marker of treatment tolerability or a predictor of treatment-related toxicity. Some patients who are fit can tolerate induction, consolidation, and even high-dose chemotherapy with autologous stem cell transplantation, whereas others who have multiple comorbidities with reduced renal and bone marrow function can tolerate only intermediate doses of methotrexate...
February 15, 2019: Acta Haematologica
https://read.qxmd.com/read/30782610/viral-immunologic-and-clinical-features-of-primary-effusion-lymphoma
#4
Kathryn Lurain, Mark N Polizzotto, Karen Aleman, Manisha Bhutani, Kathleen M Wyvill, Priscila H Gonçalves, Ramya Ramaswami, Vickie Ann Marshall, Wendell Miley, Seth M Steinberg, Richard F Little, Wyndham Wilson, Armando C Filie, Stefania Pittaluga, Elaine S Jaffe, Denise Whitby, Robert Yarchoan, Thomas S Uldrick
Primary effusion lymphoma (PEL) is an aggressive HIV-associated lymphoma with a relatively poor prognosis in the era of effective HIV therapy. Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent, and approximately 80% of tumors are Epstein Barr virus (EBV) co-infected. A better understanding of how KSHV-related immune dysregulation contributes to the natural history of PEL will improve outcomes. We identified 20 PEL patients diagnosed 2000-2013, including 19 treated with modified infusional etoposide, vincristine, and doxorubicin with cyclophosphamide and prednisone (EPOCH) and compared their clinical, virologic, and immunologic features with 20 patients with HIV-associated diffuse large B-cell lymphoma (HIV-DLBCL) and 19 patients with symptomatic interleukin (IL)-6 related KSHV-associated multicentric Castleman disease (KSHV-MCD)...
February 19, 2019: Blood
https://read.qxmd.com/read/30779873/comparison-of-outcomes-of-free-hand-2-dimensional-ultrasound-guided-versus-navigated-3-dimensional-ultrasound-guided-biopsy-for-supratentorial-tumours-a-single-institution-experience-with-125-cases
#5
Aditya D Patil, Vikas Singh, Vivek Sukumar, Prakash M Shetty, Aliasgar V Moiyadi
Purpose: The purpose of this study was to evaluate the relative utility and benefits of free-hand 2-dimensional intraoperative ultrasound (FUS) and navigated 3-dimensional intraoperative ultrasound (NUS) as ultrasound-guided biopsy (USGB) techniques for supratentorial lesions. Methods: All patients who underwent USGB for suspected supratentorial tumours from January 2008 to December 2017 were retrospectively analyzed. The charts and electronic medical records of these patients were studied...
December 8, 2018: Ultrasonography
https://read.qxmd.com/read/30779244/a-recurrent-clonally-distinct-burkitt-lymphoma-case-highlights-genetic-key-events-contributing-to-oncogenesis
#6
Dominique Penther, Pierre-Julien Viailly, Sylvain Latour, Pascaline Etancelin, Elodie Bohers, Hélène Vellemans, Vincent Camus, Anne Lise Menard, Sophie Coutant, Hélène Lanic, Emilie Lemasle, Fanny Drieux, Liana Veresezan, Philippe Ruminy, Anna Raimbault, Jean Soulier, Thierry Frebourg, Hervé Tilly, Fabrice Jardin
Burkitt lymphoma (BL) is characterized by a translocation of the MYC oncogene that leads to the upregulation of MYC expression, cell growth and proliferation. It is well-established that MYC translocation is not a sufficient genetic event to cause BL. Next-generation sequencing has recently provided a comprehensive analysis of the landscape of additional genetic events that contribute to BL lymphomagenesis. Refractory BL or relapsing BL are almost always incurable as a result of the selection of a highly chemoresistant clonally related cell population...
February 18, 2019: Genes, Chromosomes & Cancer
https://read.qxmd.com/read/30777105/requirement-for-etoposide-in-the-treatment-of-pregnancy-related-hemophagocytic-lymphohistiocytosis-a-multicenter-retrospective-study
#7
Yue Song, Zhao Wang, Zengping Hao, Lihong Li, Junli Lu, Hongjun Kang, Yanping Lu, Yanqin You, Lijuan Li, Qingyun Chen, Bo Chen
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare severe clinical syndrome. HLH manifesting during pregnancy has been paid much attention in recent years. Despite the specificity of pregnancy-related HLH, there has not been any consensus regarding its treatment. According to a previous study, corticosteroid/IVIG is the mainstream therapy; however, the efficacy is controversial. Etoposide is an important agent in the HLH-94 regimen; nevertheless, its use is limited because of possible toxicity to the fetus...
February 18, 2019: Orphanet Journal of Rare Diseases
https://read.qxmd.com/read/30775023/advance-of-theragnosis-biomarkers-in-lung-cancer-from-clinical-to-molecular-pathology-and-biology
#8
REVIEW
Christina Alidousty, Till Baar, Carina Heydt, Svenja Wagener-Ryczek, Anna Kron, Juergen Wolf, Reinhard Buettner, Anne Maria Schultheis
One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase ( ALK ). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK +-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome...
January 2019: Journal of Thoracic Disease
https://read.qxmd.com/read/30774774/high-cxcr4-expression-impairs-rituximab-response-and-the-prognosis-of-r-chop-treated-diffuse-large-b-cell-lymphoma-patients
#9
Maria Bach Laursen, Linn Reinholdt, Anna Amanda Schönherz, Hanne Due, Ditte Starberg Jespersen, Lykke Grubach, Marianne Schmidt Ettrup, Rasmus Røge, Steffen Falgreen, Suzette Sørensen, Julie Støve Bødker, Alexander Schmitz, Hans E Johnsen, Martin Bøgsted, Karen Dybkær
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagonizing cell surface receptor CXCR4. In a two-step strategy, we tested the hypothesis that prognostic value of CXCR4 in DLBCL relates to rituximab treatment, due to a hampering effect of CXCR4 on the response of DLBCL cells to rituximab...
January 22, 2019: Oncotarget
https://read.qxmd.com/read/30773271/good-outcomes-for-patients-with-classical-hodgkin-lymphoma
#10
Elizabeth Gourd
No abstract text is available yet for this article.
February 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30771874/safety-issues-with-the-alk-inhibitors-in-the-treatment-of-nsclc-a-systematic-review
#11
REVIEW
Loay Kassem, Kyrillus S Shohdy, Shaimaa Lasheen, Omar Abdel-Rahman, Ahmad Ali, Raafat R Abdel-Malek
INTRODUCTION: Oral tyrosine kinase inhibitors targeting the chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) in non-small cell lung cancer (NSCLC) were associated with superior clinical outcome. Tyrosine Kinase inhibitors (TKIs) are known to have peculiar toxicity profile, hence, increasing awareness to the safety profile of ALK inhibitors is essential. METHODS: A comprehensive systematic review of literature has been conducted to include prospective trials that used the ALK inhibitors Crizotinib, Ceritinib, Alectinib, Brigatinib and Lorlatinib in patients with advanced NSCLC and have available efficacy and toxicity results...
February 2019: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/30770396/active-surveillance-for-nodular-lymphocyte-predominant-hodgkin-lymphoma
#12
Sven Borchmann, Erel Joffe, Craig H Moskowitz, Andrew D Zelenetz, Ariela Noy, Carol S Portlock, John F Gerecitano, Connie L Batlevi, Philip C Caron, Pamela Drullinsky, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Anita Kumar, Matthew J Matasar, Alison J Moskowitz, Colette N Owens, M Lia Palomba, Anas Younes, David J Straus
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance. All patients aged 16 years or older diagnosed and followed at MSK between 1974 and 2016 were included...
February 15, 2019: Blood
https://read.qxmd.com/read/30770362/pd-l1-and-tumor-associated-macrophages-in-de-novo-dlbcl
#13
Ronald McCord, Christopher R Bolen, Hartmut Koeppen, Edward E Kadel, Mikkel Z Oestergaard, Tina Nielsen, Laurie H Sehn, Jeffrey M Venstrom
Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death-1 (PD-1), are important negative regulators of immune cell activation. Therapeutically targeting PD-1/PD-L1 in diffuse large B-cell lymphoma (DLBCL) patients with a single agent has limited activity, meriting a deeper understanding of this complex biology and of available PD-L1 clinical assays. In this study, we leveraged 2 large de novo DLBCL phase 3 trials (GOYA and MAIN) to better understand the biologic and clinical relevance of PD-L1 in de novo DLBCL...
February 26, 2019: Blood Advances
https://read.qxmd.com/read/30769194/barriers-to-allogeneic-hematopoietic-stem-cell-transplant-for-human-t-cell-lymphotropic-virus-1-associated-adult-t-cell-lymphoma-leukemia-in-the-united-states-experience-from-a-large-cohort-in-a-major-tertiary-center
#14
Diego Adrianzen Herrera, Noah Kornblum, Ana Acuna-Villaorduna, R Alejandro Sica, Urvi Shah, Moya Butler, Nivetha Vishnuvardhan, Nishi Shah, Lizamarie Bachier-Rodriguez, Olga Derman, Aditi Shastri, Ioannis Mantzaris, Amit K Verma, Ira Braunchweig, Murali Janakiram
In the United States (U.S.), Adult T-Cell Lymphoma-Leukemia (ATLL) carries a dismal prognosis and mainly affects immigrants from Human T-Cell Lymphotropic Virus 1 (HTLV-1) endemic areas. Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) can be effective and is recommended as an upfront treatment in the NCCN guidelines. We studied the barriers to alloHSCT in one of the largest ATLL populations in the U.S. Comprehensive chart and donor registry reviews were conducted for 88 ATLL patients treated at Montefiore Medical Center from 2003 to 2018...
February 12, 2019: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30769193/the-roles-of-fdg-pet-ct-in-predicting-the-adverse-effects-of-chimeric-antigen-receptor-t-cell-therapy-treating-patients-with-non-hodgkin-lymphoma
#15
Jiasheng Wang, Yongxian Hu, Shuye Yang, Guoqin Wei, Xin Zhao, Wenjun Wu, Yanlei Zhang, Yafei Zhang, Donghe Chen, Zhao Wu, Lei Xiao, Alex Hongsheng Chang, He Huang, Kui Zhao
BACKGROUND: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden...
February 12, 2019: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30769175/outcomes-after-reduced-dose-intensity-modulated-radiation-therapy-for-gastric-mucosa-associated-lymphoid-tissue-malt-lymphoma
#16
Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Ruben J Cruz Chamorro, L Jeffrey Medeiros, Joseph D Khoury, Behrang Amini, Sattva Neelapu, Hun Lee, Jason Westin, Nathan Fowler, Loretta Nastoupil, Bouthaina Dabaja
PURPOSE/OBJECTIVES: In patients with gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma), the standard radiation therapy (RT) dose is ≥ 30 Gy. We report the outcome of patients treated with reduced 24 Gy compared with ≥ 30 Gy. MATERIALS/METHODS: We reviewed 32 patients diagnosed between 2007 and 2017 with gastric MALT lymphoma and treated with involved site radiation therapy (ISRT) using intensity modulated radiation therapy (IMRT)...
February 12, 2019: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/30768440/sox11-negative-mantle-cell-lymphoma-clinicopathologic-and-prognostic-features-of-75-patients
#17
Jie Xu, Lifu Wang, Jingyi Li, Annapurna Saksena, Sa A Wang, Jing Shen, Zhihong Hu, Pei Lin, Guilin Tang, C Cameron Yin, Michael Wang, L Jeffrey Medeiros, Shaoying Li
Studies have suggested that SOX11 expression has prognostic implications in patients with mantle cell lymphoma (MCL), but the data are controversial. In this study, we describe the clinicopathologic and prognostic features of 75 patients with SOX11-negative MCL. Compared with patients with SOX11-positive MCL, SOX11-negative MCL patients more frequently had leukemic non-nodal disease (21% vs. 4%, P=0.0001). SOX11-negative MCLs more often showed classic morphology (83% vs. 65%, P=0.005), were more often positive for CD23 (39% vs...
February 12, 2019: American Journal of Surgical Pathology
https://read.qxmd.com/read/30766857/primary-gastrointestinal-diffuse-large-b-cell-lymphoma-a-prospective-study-from-south-india
#18
Babu Suresh, Vikas Asati, K C Lakshmaiah, Govind Babu, D Lokanatha, Linu Abraham Jacob, K N Lokesh, A H Rudresh, L K Rajeev, Saldanha Smitha, Abhishek Anand, Rajesh Patidar, C S Premalata
Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and treatment outcome of primary GIT diffuse large B-cell lymphoma (PGIL). Materials and Methods: Newly diagnosed patients of PGIL with DLBCL histology were eligible. Lugano staging system was used. All patients were treated with prephase treatment (1 mg vincristine and 100 mg prednisolone) followed by CHOP-based chemotherapy (with or without rituximab) as definitive treatment...
January 2019: South Asian Journal of Cancer
https://read.qxmd.com/read/30764632/development-of-resistant-gvhd-in-a-patient-treated-with-nivolumab-for-hodgkins-lymphoma-relapse-after-allogeneic-unrelated-transplantation
#19
K Steinerová, P Jindra, D Lysák, M Karas
BACKGROUND: Allogeneic hematopoietic stem cell transplantation is one of the therapeutic options for patients with relapsed or refractory classic Hodgkins lymphoma (cHL). In the case of dis-ease relapse after transplant, other treatment options are still limited (for example donor lymphocyte infusion, and chemother-apy with brentuximab, bendamustine, or other agents) with uncertain outcomes in terms of patient tolerance and long-term dis-ease remission. One way to achieve remission is administration of the PD-1 inhibitor nivolumab, a PD-1 checkpoint inhibitor...
2019: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://read.qxmd.com/read/30764603/body-cavity-based-lymphoma-in-a-country-with-low-human-immunodeficiency-virus-prevalence-a-series-of-17-cases-from-the-consortium-for-improving-survival-of-lymphoma
#20
Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh
Purpose: Primary effusion lymphoma (PEL) is a type of body cavity-based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. Materials and Methods: We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea...
February 14, 2019: Cancer Research and Treatment: Official Journal of Korean Cancer Association
keyword
keyword
162410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"